Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Clinical Efficacy Assessment of Digitally Fabricated PEEK Barrier Membranes for Guided Bone Regeneration in Severe Bone Defects

31. oktober 2026 oppdatert av: Fuming He
  1. Research background: Guided bone regeneration (GBR), as a bone augmentation technique, is widely used for the reconstruction of hard-tissue defects in implant dentistry. Terheyden classified bone defects into four types according to the spatial relationship between the defect and the intended implant site. Among these, type 2/4, 3/4, and 4/4 are recommended to be managed with a staged protocol: bone augmentation first, followed by dental implant placement. The selection of barrier membranes for GBR depends on the size of the bone defect, and severe three-dimensional bone deficiencies require additional mechanical support. The digitally fabricated PEEK biological barrier is a product of the world's first digital PEEK bone augmentation system newly developed by Kangtuo Medical Group in 2026. It enables predictable bone gain and contour reconstruction, adapts to irregularly shaped bone defects, and provides complete cell exclusion as well as full soft-tissue isolation without the need for an overlying membrane. The system supports full-workflow planning and clinician-driven design. Being radiolucent, it facilitates sequential observation of bone remodeling, and the device is also easy to retrieve. Nevertheless, its clinical performance following GBR in severe bone defect sites remains to be further evaluated.
  2. Research objective: To evaluate the bone stability and soft tissue healing outcomes following guided bone regeneration (GBR) using a digital PEEK biological barrier in sites with severe bone defects. This study aims to provide evidence based references for clinicians when selecting barrier membranes, so as to facilitate optimal clinical decision making for bone augmentation.
  3. Study design and methods: Design type: multicentral prospective clinical study. Study duration: 3 years. Start time: From the date of adoption of ethics. End time: 2029. For all included patients, cone beam computed tomography (CBCT) scans and intraoral scans will be performed preoperatively, immediately postoperatively, and at 6-8 months postoperatively.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

  1. Research background: Guided bone regeneration (GBR), as a bone augmentation technique, is widely used for the reconstruction of hard-tissue defects in implant dentistry. Terheyden classified bone defects into four types according to the spatial relationship between the defect and the intended implant site. Among these, type 2/4, 3/4, and 4/4 are recommended to be managed with a staged protocol: bone augmentation first, followed by dental implant placement. The selection of barrier membranes for GBR depends on the size of the bone defect, and severe three-dimensional bone deficiencies require additional mechanical support. The digitally fabricated PEEK biological barrier is a product of the world's first digital PEEK bone augmentation system newly developed by Kangtuo Medical Group in 2026. It enables predictable bone gain and contour reconstruction, adapts to irregularly shaped bone defects, and provides complete cell exclusion as well as full soft-tissue isolation without the need for an overlying membrane. The system supports full-workflow planning and clinician-driven design. Being radiolucent, it facilitates sequential observation of bone remodeling, and the device is also easy to retrieve. Nevertheless, its clinical performance following GBR in severe bone defect sites remains to be further evaluated.
  2. Research objective: To evaluate the bone stability and soft tissue healing outcomes following guided bone regeneration (GBR) using a digital PEEK biological barrier in sites with severe bone defects. This study aims to provide evidence based references for clinicians when selecting barrier membranes, so as to facilitate optimal clinical decision making for bone augmentation.
  3. Study design and methods: Design type: multicentral prospective clinical study. Study duration: 3 years. Start time: From the date of adoption of ethics. End time: November 2029. All patients who meet the inclusion criteria at seven study centers will be recruited starting from the date of ethical approval. Each center plans to enroll 2-6 participants. Patients with severe bone defects are screened via pre-implant radiographic examinations for eligibility. All subjects provide written informed consent prior to enrollment in the clinical study. Baseline information including sex, age, and missing tooth position is recorded for all participants. Routine pre-implant assessments are performed at baseline (T0), consisting of radiographic examinations (panoramic radiograph and CBCT), intraoral examination, and pre-surgical intraoral scanning. Based on the intraoral scan and CBCT datasets, the designer reconstructs the original model and simulates the crown contour after bone graft placement, then designs and fabricates the customized PEEK biological barrier. All surgical procedures are performed by one experienced clinician at each participating center. Immediately after surgery (T1), CBCT is obtained to evaluate vertical and horizontal bone augmentation. Suture removal and intraoral scanning are conducted at 2 weeks post GBR to document soft tissue contour, together with patient satisfaction assessed using a visual analogue scale (VAS). At 6-8 months after GBR (T2), intraoral scanning and CBCT are performed to verify whether the augmented bone volume is adequate for implant placement. Subsequently, the PEEK biological barrier is removed, and implants with appropriate diameter and length are inserted. The collected data are analyzed to evaluate bone stability and soft tissue healing outcomes following GBR using the digitally fabricated PEEK biological barrier in sites with severe bone defects.

Studietype

Intervensjonell

Registrering (Antatt)

26

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Fuming He
  • Telefonnummer: +8613516817697
  • E-post: hfm@zju.edu.cn

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Aged between 18 and 80 years, in good general health or with mild and controllable systemic diseases, and capable of tolerating implant surgery.
  2. Patients with at least one missing tooth, whose bone defect at the edentulous site is classified as type 2/4, 3/4 or 4/4 according to the Terheyden classification.
  3. If bilateral bone augmentation is required, only one side will be randomly selected for inclusion in this study.
  4. The tooth at the surgical site has been extracted for at least 3 months, and the site is surgically naive.
  5. Sufficient soft tissue contour for staged bone augmentation, including a keratinized gingiva width of at least 2 mm.
  6. All patients undergo bone grafting supported by a digitally fabricated PEEK biological barrier followed by implant placement.
  7. Good oral hygiene status.
  8. Patients are able to understand and actively cooperate with the treatment protocol and have signed the informed consent form.

Exclusion Criteria:

  1. Pregnancy.
  2. Smoking more than 10 cigarettes per day.
  3. Subjects with alcohol abuse or chronic substance misuse.
  4. Long-term use of medications that interfere with bone formation.
  5. Presence of physical deformities that may compromise implant surgery.
  6. A history of local radiotherapy.
  7. Patients with immunodeficiency, including those with HIV infection.
  8. Local inflammation, including untreated periodontitis.
  9. Extensive metallic restorations adjacent to the bone augmentation site.
  10. Oral mucosal disorders, such as oral lichen planus.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PEEK barrier membrane
Enhet: PEEK barrier membrane

Implantation of a PEEK biological barrier during guided bone regeneration in the area of severe bone deficiency

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Bone augmentation
Tidsramme: From enrollment to the end of treatment at 6 months

The cone beam computed tomography (CBCT) data from the two time points (on the day of the initial consultation (T0), and six-eight months after the first surgery (T2) ) were obtained and imported into Mimics Medical software. For each patient, the jaw models at T2 were aligned separately with the jaw model at T0 using point and global registration. After registration and cutting of the digital models, , a Boolean subtraction operation was conducted by subtracting the pre-operative bone segment from the bone segment at 6 months postoperatively to obtain a 6-month postoperative bone increment model. The volumes of the 6-month bone increment can be accessed from the properties menu.
From enrollment to the end of treatment at 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Bone resorption
Tidsramme: From enrollment to the end of treatment at 6 months

The cone beam computed tomography (CBCT) data from the three time points (on the day of the initial consultation (T0), immediately after surgery (T1) and six months after the first surgery (T2) ) were obtained and imported into Mimics Medical software. For each patient, the jaw models at T1 and T2 were aligned separately with the jaw model at T0 using point and global registration. After registration and cutting of the digital models, , a Boolean subtraction operation was conducted by subtracting the pre-operative bone segment from the bone segment at 6 months postoperatively to obtain a 6-month postoperative bone increment model. V1 (volumes of the immediate bone increment) and V2 (volumes of the 6-month bone increment) can be accessed from the properties menu. The resorption rate of bone increment, denoted as RV, can be calculated by utilizing the formula (V1 -V2)/V1.
From enrollment to the end of treatment at 6 months
Bone height change
Tidsramme: From enrollment to the end of treatment at 6 months

The STL files of the preoperative bone defect region, immediate postoperative augmented bone, and bone at 6 months postoperatively were imported into the E-3D implant design software with a unified coordinate system. These files were then registered to the CBCT datasets, and the implant site was planned. Using the long axis of the virtually designed implant, an inspection plane was created in the buccolingual direction, from which two-dimensional measurements were acquired. The STL models of bone contours at the three time points were visualized in 2D within the E-3D software. The linear distance between T0 and T2 was recorded as the augmented bone height (H1), and the linear distance between T1 and T2 was recorded as the bone height after six months of healing (H2). The difference between H1 and H2 represented the bone height resorption over the six-month healing period.
From enrollment to the end of treatment at 6 months
Patient satisfaction
Tidsramme: From enrollment to the end of treatment at 6 months

postoperative satisfaction through VAS assessment
From enrollment to the end of treatment at 6 months
pseudo-periosteum
Tidsramme: At the time of implant placement in the second phase surgery

A periodontal probe was used to measure the pseudo-periosteal thickness at the buccal, palatal, and alveolar crest sites around each implant.
At the time of implant placement in the second phase surgery
Soft tissue healing
Tidsramme: From enrollment to the end of treatment at 6 months

Soft tissue healing condition recorded by oral scanning and photography in 2 weeks before and 2 weeks after surgery and 6-8 months after surgery.
From enrollment to the end of treatment at 6 months
Bone width change
Tidsramme: From enrollment to the end of treatment at 6 months

The STL files of the preoperative bone defect, immediate postoperative augmented bone, and bone at 6 months postoperatively were imported into the E-3D implant design software under a unified coordinate system. These files were then registered to the CBCT datasets, and the implant site was virtually planned. Using the long axis of the designed implant, an inspection plane was generated in the buccolingual direction for two-dimensional measurement acquisition. The STL models of bone contours at the three time points were visualized in 2D within the E-3D software. For horizontal bone defects, a line perpendicular to the long axis of the designed implant was drawn at the level of the implant platform. Three segment lengths were captured to represent the bone width at baseline, immediately after surgery, and at 6 months postoperatively, respectively. Pairwise subtraction of these values yielded the immediate width gain, the width gain at 6 months, and the width resorption.
From enrollment to the end of treatment at 6 months
Biological complication
Tidsramme: From enrollment to the end of treatment at 6 months

Logging PEEK barrier exposure, infection, bone Implantation Failure, etc.
From enrollment to the end of treatment at 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Fuming He

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

3. november 2026

Primær fullføring (Antatt)

30. august 2029

Studiet fullført (Antatt)

30. november 2029

Datoer for studieregistrering

Først innsendt

31. oktober 2026

Først innsendt som oppfylte QC-kriteriene

31. oktober 2026

Først lagt ut (Faktiske)

5. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

31. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • DHZhejiangU-2026(155)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere